Synact ready for phase II with arthritis candidate: "An important milestone for the company"

After finishing phase I trials, Danish biotech company Synact has applied for the authorities' permission to initiate a phase II study with the company's lead candidate against rheumatoid arthritis. According to the CEO, the company has various financing opportunities.

Photo: Synact Pharma PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles